Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: A randomized phase II trial

Giorgio Cocconi, Giancarlo Bisagni, Guido Ceci, Beatrice Di Blasio, Vincenzo De Lisi, Rodolfo Passalacqua, Alvise Zadro, Corrado Boni, Paolo Morandi, Luisa Savoldi

Research output: Contribution to journalArticle

Abstract

We designed three new four-drug cisplatin-containing combinations and evaluated their activity in a randomized phase II study including patients with locally advanced (stags III) and locally recurrent breast carcinoma. All combinations included methotrexate (M) on day 1 and cisplatin (P) on day 2 (MVAC-like combinations) and differed from one another by the addition of Epirubicin (Epi), Vincristine (V), Etoposide (E), Mitomycin (Mi). Based on the administered agents, they were named MPEMi, MPEpiE, MPEpiV. The combinations were randomly assigned to 101 patients, 57 with locally advanced and 44 with locally recurrent breast carcinoma. Response was evaluated after 4 cycles. The complete response (CR) rates were 7% and 43% and the CR plus partial response (PR) rates were 84% and 89% in locally advanced and in locally recurrent disease, respectively. In locally advanced disease, a pathologic CR (pCR) was assessed in seven of 57 patients (12%). There were no significant differences among the three combinations. The toxicities were at times severe, but generally tolerable, as demonstrated by the high cumulative doses of the drugs received by the patients. In conclusion, these three innovative chemotherapy regimens induced high CR plus PR rates in the neoadjuvant treatment of stage III and of locally recurrent breast carcinoma, and a high rate of pCR in stage III disease. These regimens warrant testing in phase III trials.

Original languageEnglish
Pages (from-to)125-132
Number of pages8
JournalBreast Cancer Research and Treatment
Volume56
Issue number2
Publication statusPublished - 1999

    Fingerprint

Keywords

  • Breast carcinoma
  • Cisplatin
  • Loco-regional recurrence
  • Primary chemotherapy
  • Stage III

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cocconi, G., Bisagni, G., Ceci, G., Di Blasio, B., De Lisi, V., Passalacqua, R., Zadro, A., Boni, C., Morandi, P., & Savoldi, L. (1999). Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: A randomized phase II trial. Breast Cancer Research and Treatment, 56(2), 125-132.